Literature DB >> 2185802

Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review.

G Lehne1, K Lote.   

Abstract

Cytotoxic agents may cause interstitial or eosinophilic pneumonitis, alveolar proteinosis, pulmonary venous occlusive disease, pulmonary fibrosis, pneumothorax, or pulmonary oedema. These agents may also potentiate lung injury caused by radiotherapy or high oxygen fractions in inspired air. Clinical and roentgenological features of lung damage induced by cytotoxic drugs are usually non-specific, and differential diagnoses include progression of the malignant disease and a plethora of opportunistic infections. Monitoring of blood gases and carbon monoxide transfer factor may facilitate early detection of drug induced lung injury. Fiberoptic bronchoscopy, bronchoalveolar lavage, transbronchial biopsy, or open lung biopsy may be necessary for reliable diagnosis. Early detection of lung damage and immediate withdrawal of the responsible agent(s) are essential. Steroids may be of therapeutic value in some patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185802     DOI: 10.3109/02841869009126530

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  11 in total

Review 1.  Secondary alveolar proteinosis in cancer patients.

Authors:  S Ladeb; J Fleury-Feith; E Escudier; J Tran Van Nhieu; J F Bernaudin; C Cordonnier
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

2.  A report on serious pulmonary toxicity associated with gemcitabine-based therapy.

Authors:  Debasish F Roychowdhury; Catherine A Cassidy; Patrick Peterson; Michael Arning
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

3.  Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin.

Authors:  S Koldsland; J L Svennevig; G Lehne; E Johnson
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

4.  Methotrexate-induced pericarditis and pericardial effusion; first reported case.

Authors:  L N Forbat; B W Hancock; A H Gershlick
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

5.  Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.

Authors:  Denise Bernhardt; Wolfgang Wick; Stephanie E Weiss; Arjun Sahgal; Simon S Lo; John H Suh; Eric L Chang; Matthew Foote; James Perry; Bernhard Meyer; Peter Vajkoczy; Patrick Y Wen; Christoph Straube; Steffi Pigorsch; Jan J Wilkens; Stephanie E Combs
Journal:  Neuro Oncol       Date:  2020-05-05       Impact factor: 12.300

6.  Challenges in lung cancer therapy during the COVID-19 pandemic.

Authors:  Luana Calabrò; Solange Peters; Jean-Charles Soria; Anna Maria Di Giacomo; Fabrice Barlesi; Alessia Covre; Maresa Altomonte; Virginia Vegni; Cesare Gridelli; Martin Reck; Naiyer Rizvi; Michele Maio
Journal:  Lancet Respir Med       Date:  2020-04-09       Impact factor: 30.700

7.  Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin.

Authors:  G Lehne; B Johansen; S D Fosså
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

8.  Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

Authors:  S D Fosså; J P Droz; G Stoter; S B Kaye; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation.

Authors:  U Blom Goldman; M Anderson; B Wennberg; P Lind
Journal:  J Radiother Pract       Date:  2013-06-07

10.  Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.

Authors:  David Rossi
Journal:  Lung Cancer       Date:  2020-05-06       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.